Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the 'Company'), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced earlier this month it has engaged a prominent government and political affairs consulting and lobbying firm to support its mission of advancing psychedelic-based treatments.
As psychedelics gain traction in the pharmaceutical industry for their potential to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, Clearmind recognizes the importance of navigating complex regulatory landscapes and fostering greater acceptance among policymakers in the U.S.. The company's partnered with the esteemed firm to support the integration of psychedelic therapies into mainstream healthcare by advocating for informed, science-based regulatory frameworks.
'We are pleased to collaborate with a team of seasoned government affairs experts to help shape the future of psychedelic medicine,' said Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine. 'Psychedelics hold immense promise for transforming mental health treatment, but their novelty requires proactive engagement with regulators and policymakers to ensure safe and equitable access. This partnership underscores our commitment to driving progress in this rapidly evolving field.'
The consulting firm, known for its expertise in navigating federal and state regulatory environments, will work closely with Clearmind to educate policymakers on the therapeutic potential of psychedelics, support the development of balanced regulations, and foster strategic alliances to advance the company's innovative pipeline, including its lead candidate, CMND-100, currently in Phase I/IIa clinical trials for AUD at prestigious institutions like Yale School of Medicine and Johns Hopkins University.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol 'CMND' and the Frankfurt Stock Exchange under the symbol 'CWY0.'
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
[email protected]
Telephone: (604) 260-1566
US: [email protected]
General Inquiries
[email protected]
www.Clearmindmedicine.com
Forward-Looking Statements:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Pink Floyd pilot and former army officer honoured for work combating PTSD
A FORMER Army Officer and Royal Navy Commando pilot, who works as the pilot for band Pink Floyd, has been honoured for his work combating PTSD. Tim Boughton, 54, who used to live in Kempsey but now lives in Hampshire was awarded an honorary degree by Middlesex University for his work with serving veteran and emergency services personnel. "It is humbling to be recognised in this way amongst a cohort of truly amazing people," said Mr Boughton. "I never thought that at 54 I would be able to receive such an honour, especially as I was not up to much through school. "For me the importance is using this platform to further the work in the mindfulness and mental health arena and to collaborate closely with the university to see how we can make peoples' lives better in an uncertain world. "Our ability to help others and understand how we can adapt amongst such uncertainty must be at the forefront of what we do." READ MORE: Hunt for good Samaritans who helped after woman reportedly fell into river READ MORE: Woman in her 90s left terrified after finding burglar in living room READ MORE: Boy injured in 'vicious' attack at food and music festival With a background in the army as an infantry officer and as a commando helicopter pilot with the Royal Navy, the 54-year-old overcame his own mental health issues -including PTSD - inspiring his mission to impower others. He has since become a speaker and global advisor in cognitive performance and mental health, alongside working as the pilot for the band Pink Floyd. In 2019, he was appointed as the specialist advisor to the British Army for mental health and has given evidence on numerous occasions to Parliament. He went on to complete a Master's degree in Mindful Based Cognitive Therapy at Oxford University, and is on the way to attaining a second Masters in psychology. His study of more than 280 mental health apps led to the creation of an award-winning six week programme that has saved lives and transformed approaches in trauma care for elite personnel in the military and sport.
Yahoo
39 minutes ago
- Yahoo
A crucial jobs report meets a stock market at all-time highs: What to know this week
The S&P 500 (^GSPC) is back at an all-time high for the first time since February as optimism around Federal Reserve interest rate cuts and fading fears of tariffs have driven stocks higher. In the final full trading week of June, the S&P 500 rose 3.5%, while the Nasdaq Composite (^IXIC) rose more than 4.1%. Both indexes ended the week at all-time highs. Meanwhile, the Dow Jones Industrial Average (^DJI) added about 3.8%. The June jobs report will headline the first week of July. Fresh readings on job openings and wage data, as well as manufacturing and services activity, will also be in focus for investors. Investors will also have a close eye on any updates regarding President Trump's various tariff pauses ahead of the administration's self-imposed tariff delay deadline on July 9. Markets will close at 1 p.m. on Thursday and remain shut on Friday for the Fourth of July. Markets are increasingly optimistic that the Federal Reserve may cut interest rates soon. As of Friday, markets were pricing in an 18.6% chance the central bank cuts interest rates at its next meeting in late July, up from a 14.5% chance seen last week, per the CME FedWatch Tool. Meanwhile, probability investors are placing on a cut by the end of September has surged, with markets now pricing in a 93% chance the central bank will have lowered rates by then, up from a 70% chance seen just a week ago. The shift comes as several Fed officials have alluded to the possibility of cutting interest rates as soon as the central bank's July meeting. In a speech on June 23, Federal Reserve governor Michelle Bowman noted that although the labor market is showing signs of strength, it "appears to be less dynamic." "With inflation on a sustained trajectory toward 2%, softness in aggregate demand, and signs of fragility in the labor market, I think that we should put more weight on downside risks to our employment mandate going forward," Bowman said. However, Fed Chair Jerome Powell has been more cautious about interest rate cuts. While testifying in front of House lawmakers last week, Powell stressed that the central bank is "well-positioned to wait" before moving interest rates. EY chief economist Greg Daco told Yahoo Finance he believes the Fed will likely cut in September. "By then we will have seen more demand erosion, we will have seen a labor market that unfortunately has slowed and income growth as a result has slowed, leading to slower consumer spending activity," Daco said. Signs of cooling in the labor market have been a key part of the brewing debate over Fed policy and will put further emphasis on the incoming June jobs report, due out for release at 8:30 a.m. ET on Thursday. Economists expect the report to show 116,00 nonfarm payrolls were added, a move lower from the 139,000 seen in May. The unemployment rate is anticipated to have moved up to 4.3% from 4.2% the month prior. "We expect the moderation in hiring to continue," Wells Fargo's team of economists led by Jay Bryson wrote in a note to clients on Friday. " Demand for new workers remains muted amid still-elevated uncertainty, restrictive monetary policy and the ongoing federal government hiring freeze." The S&P 500's most recent record close comes as the market has rallied more than 23% from its April 8 bottom. Now, strategists believe the market's largest tariff fears are behind investors. Economic forecasts have once again begun reverting higher, along with projections for corporate earnings this year. And Wall Street strategists are becoming incrementally bullish on the outlook from here. As our chart below shows, the S&P 500 has chugged past a slew of headwinds to hit a record high this year. "The market still does tend to have a bullish sentiment to it," Charles Schwab head of trading and derivatives strategist Joe Mazzola told Yahoo Finance. "So I think you're seeing investors looking for those opportunities on pullbacks to buy in." Weekly Calendar Earnings: No notable earnings releases. Economic data: MNI Chicago PMI, June (42.7 expected, 40.5 prior); Dallas Fed manufacturing activity Earnings: Constellation Brands (STZ) Economic data: JOLTS Job Openings, May (7.26 million expected, 7.39 previously); ISM manufacturing, June (48.8 expected, 48.5 prior); Construction spending month-over-month, May (+0.1% expected, -0.4% prior); Dallas Fed services activity (-10.1 prior); S&P Global US manufacturing PMI, June (52 expected, 52 prior) Wednesday Earnings: No notable earnings. Economic data: MBA Mortgage Applications, week ending June 27 (+1.1% previously); ADP employment change, June (90,000 expected, 37,000 expected); S&P Global US services PMI, May final (52.3 expected, 52.3 prior); Challenger job cuts year-over-year, May (+62.7% prior) Earnings: No notable earnings Economic data: Nonfarm payrolls, June (+110,000 expected, +129,000 previously); Unemployment rate, June (4.3% expected, 4.2% previously); Average hourly earnings, month over month, June (+0.3% expected, +0.4% previously); Average hourly earnings, year over year, June (+3.8% expected, +3.9% previously); Average weekly hours worked, June (34.3 expected, 34.3 previously); Labor force participation rate, June (62.5% expected, 62.4% previously); Initial jobless claims week ending June 28 (240,000 expected, 236,000 prior); Continuing claims week ending May 24 (1.91 million prior); Nonfarm productivity, first quarter final (-0.8% expected, -0.8% prior); Unit labor costs, first quarter final (+5.7% expected, +5.7% prior); S&P Global US Composite PMI, June final (52.8 prior); ISM Services index, June (50.7 expected, 49.4prior); Federal Reserve Beige Book released; Durable goods orders, May final (16.4% prior) Markets are closed for the Fourth of July. Josh Schafer is a reporter for Yahoo Finance. Follow him on X @_joshschafer.
Yahoo
an hour ago
- Yahoo
This Psychedelic Drug Flopped on Trial Results. Should You Buy the Dip?
Psychedelic stocks are gaining attention as new ways to treat mental illnesses like depression and post-traumatic stress disorder (PTSD). Companies in the niche use substances like psilocybin to develop treatments that present alternatives to traditional pharmaceutical compounds. Investors are hopeful, but the road to approval is risky and drawn out. Compass Pathways (CMPS) just faced one of those setbacks when it ran a late‐stage (Phase 3) trial of its synthetic psilocybin drug (COMP360) in 258 adults with treatment-resistant depression. Those receiving the treatment had a 3.6-point greater reduction in symptoms versus those receiving the placebo, which met the trial's predefined goal of at least a 3-point difference, but came up short of the 5-point gap Wall Street had hoped for. As a result, shares plunged nearly 50% on Monday, June 23. Analysts: AMD Stock Will 'Close the Gap' With Nvidia by 2026. Should You Buy AMD Stock Here? The Saturday Spread: Data-Driven Trades That Cut Through the Noise (GILD, MCD, DJT) Why This Wildcard Stock Could Be a Future Star Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Despite the drop, analysts remain mostly bullish. The company has another major trial underway, with results expected next year. If that data is stronger, the stock could rebound sharply. Compass is also pushing ahead in studies for PTSD. For investors who believe in the future of mental health innovation, this dip might be an opportunity to get in at a better price. Based in London, Compass Pathways is a biotechnology company focused on developing innovative treatments for mental health conditions, primarily targeting psilocybin for treatment-resistant depression (TRD). Valued at $248 million in market cap, shares of this psychedelic drug company have plunged 54% over the past 52 weeks and are down 27% year to date, significantly underperforming the broader S&P 500 Index ($SPX). After the haircut, CMPS is more attractively valued with a price-book ratio of 1.31x, significantly cheaper than the sector median of 2.7x. This pricing suggests CMPS may offer a good entry point relative to its peers. While COMP360 met its goal in the COMP005 trial, the modest 3.6-point improvement disappointed markets, causing a sharp stock correction. Still, Compass Pathways is gearing up for a key catalyst in 2026, its 26-week readout from two Phase 3 trials testing its psilocybin-based treatment for treatment-resistant depression (TRD). While earlier data showed promising six- and twelve-week effects, investors remain cautious about long-term durability and patient variability. Some fear the treatment may be too niche or selective, especially with reports of adverse events in prior trials. Still, if the results are positive, Compass could gain serious momentum toward FDA approval. Compass Pathways appears to be on stable financial footing as it advances its clinical programs. In Q1 2025, the company reported $260.1 million in cash and cash equivalents. This capital base was secured through a combination of financing mechanisms, including a private investment in public equity (PIPE) deal, a loan agreement with Hercules Capital, and an established at-the-market (ATM) offering program. With a current quarterly cash burn of approximately $49.6 million, comprising $30.9 million in research and development expenses and $18.7 million in general and administrative costs, Compass projects that its existing cash reserves will support operations through the second half of 2026. This timeline aligns with the anticipated data release from its ongoing Phase 3 COMP006 trial. Wall Street analysts remain confident about the company's future growth prospects, as reflected in their consensus 'Strong Buy' rating. Among the 10 analysts covering the stock, eight rate it a 'Strong Buy,' one gives a 'Moderate Buy,' and one rates it a 'Hold.' The 12-month average price target is $16.40, implying upside potential of 483% from current levels. Compass Pathways is still a high-risk bet, with regulatory hurdles and clinical uncertainty ahead. But for investors who believe in the future of psychedelic medicine, this dip could be an attractive entry. While caution is warranted, the upside remains compelling for those with a long-term view. On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
